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ABSTRACT 
Eicosanoids and related species are critical, small bioactive mediators of human physiology 
and inflammation. While ~1100 distinct eicosanoids have been predicted to exist, to date, 
less than 150 of these molecules have been measured in humans, limiting our 
understanding of eicosanoids and their role in human biology. Using a directed non-targeted 
mass spectrometry approach in conjunction with computational chemical networking of 
spectral fragmentation patterns, we find over 500 discrete chemical signals highly 
consistent with known and putative eicosanoids in human plasma, including 46 putative 
novel molecules not previously described, thereby greatly expanding the breath of prior 
analytical strategies. In plasma samples from 1500 individuals, we find members of this 
expanded eicosanoid library hold close association with markers of inflammation, as well as 
clinical characteristics linked with inflammation, including advancing age and obesity. These 
experimental and computational approaches enable discovery of new chemical entities and 
will shed important insight into the role of bioactive molecules in human disease. 
 
 
 
  
INTRODUCTION 
Eicosanoid and eicosanoid-like molecules (collectively termed ‘eicosanoids’) represent 
small polar lipid metabolites produced through extensive and variable oxidation of mainly 18 
to 22 carbon polyunsaturated fatty acids (PUFA's), including omega-6 fatty acids, such as 
arachidonic acid, linoleic acid, and adrenic acid, and omega-3 fatty acids, such as 
docosahexaenoic acid (DHA), docosapenaenoic acid (DPA), and eiocosapentaenoic acid 
(EPA).
1-7
 Given their chemical diversity, hundreds to thousands of theoretically possible 
eicosanoid chemical compounds have been catalogued in databases worldwide, subdivided 
into chemical and functional families including prostaglandins, leukotrienes, and resolvins, 
among others.
8
 Eicosanoids are highly conserved among species, originating in elementary 
microbes and present in fungi, plants and mammals.
9-12
 Eicosanoids signal through cell 
surface G-protein coupled receptors, tyrosine kinase receptors and intracellular nuclear 
receptors, mediating a number of diverse homeostatic functions in humans including host 
immune activation, cellular development, ion transport, muscle contraction, thrombosis, and 
vasomotor tone, as well as likely many yet undiscovered processes.
13-17
 In the setting of 
acute infection, eicosanoids directly regulate the classic inflammatory triad of fever, edema 
and pain and provide early benefit by promoting clearing of invasive pathogens and wound 
healing.
3,18-24
 Eicosanoids have also been implicated in the setting of chronic aseptic 
systemic inflammation, as is associated with a number of human diseases including obesity, 
diabetes, cardiovascular disease, cancer, and autoimmunity.
25-31
 Given their profound 
biological effects, eicosanoids have been extensively targeted for therapeutic purposes with 
pharmaceutical agents, including non-sterol anti-inflammatory drugs (NSAIDs) such as 
acetylsalicylic acid (aspirin), being among the most widely utilized medications in medicine 
today.
3,5
  
Current understanding of eicosanoid biology is limited, however, by technical challenges 
related to the measure of eicosanoids, owing to their low abundance, dynamic nature, and 
extensive isometry in chemical structure.
32-34
 To date, measurement of eicosanoids has 
required highly sensitive, liquid chromatography-mass spectrometry (LC-MS) systems using 
triple-quadrupole (QQQ) based targeted analysis of known eicosanoid entities. Given the 
limited availability of commercial eicosanoid standards, much of eicosanoid biology has 
therefore focused on a well-established subset of 50-150 eicosanoid compounds, with 
typical studies reporting ~50 eicosanoids per sample, capturing only a small fraction of total 
eicosanoid biology.
35-39
 These targeted approaches have limited the study of eicosanoids as 
well as notably preclude discovery of novel eicosanoids that may be mediating tissue and 
host biology.   
Herein, to greatly expand the repertoire of eicosanoids assayed in humans, we develop a 
“directed non-targeted mass spectrometry” approach using a high mass accuracy LC-MS 
for measurement of bioactive lipid species. Using chemical networking of MS/MS spectral 
fragments and system analysis of chemical patterning we find over 500 distinct eicosanoid 
entities in human plasma, including 362 eicosanoids not previously documented in humans, 
and 46 putative novel eicosanoids not previously described. In plasma samples across 
1500 individuals, we find a number of specific and novel eicosanoids as highly associated 
with markers of systemic inflammation and common clinical characteristics linked to 
inflammatory diseases, including advancing age and increasing obesity. These analytical 
approaches greatly expand the spectrum of eicosanoids observable in complex organisms, 
enable discovery of new eicosanoids in humans, and provide a foundation for new insight 
into the role of bioactive lipids in mediating human health and disease. 
 
RESULTS 
Chemical Characterization of Eicosanoids 
Comprehensive detection of eicosanoids in a complex milieu, particularly for those chemical 
species for which no commercial standards or reference data exist, requires distinguishing 
chemical features. We therefore first sought to pinpoint common chemical characteristics 
unique to eicosanoids. Review of the LIPID MAPS chemical database (www.lipidmaps.org, 
March 2017 version) revealed 1125 theoretical, structurally distinct molecules classified as 
eicosanoids (Table S-1).
8
 Virtually all eicosanoids were found to lie within a narrow mass 
range of 300-400 daltons. Additionally, all eicosanoids contain high degrees of oxidation 
and unsaturation relative to other biomolecules within this same mass window, resulting in 
abnormally high mass defect, or the non-whole number portion of a compounds mass. 
Given the combinatorial nature of their biosynthesis, eicosanoids were also found to exhibit 
extensive isomerism wherein the 1125 theoretical eicosanoids derived from only 168 unique 
chemical formulas (Fig. 1a), and 786 of the 1125 eicosanoid compounds stem from only 23 
unique chemical formulas. To determine if these 168 eicosanoid chemical formulas occupy 
unique masses relative to other biomolecules, the accurate mass for each formula was 
searched against the 75,000 compounds present in the Human Metabolome Database 
(HMDB) using a 2 ppm mass error window.
40
 Of the 168 formulas, only 9 formulas (~5%) 
returned additional matches to non-eicosanoid compounds with the majority of these 
mapping to sterol, bile acid and free fatty acid metabolites, thereby suggesting that 
eicosanoids exhibit fairly specific and unique mass characteristics.  
To determine whether eicosanoids may be further experimentally distinguished particularly 
from isobaric, non-eicosanoid species including sterol, bile acid and free fatty acid 
metabolites, we utilized a ‘directed, non-targeted’ SPE-LC-MS approach with offline solid 
phase extraction for enrichment of eicosanoid species, reverse phase chromatography, and 
high mass accuracy mass spectrometry operating in full scan mode (see Methods). 
Commercial standards for 238 eicosanoids, 18 bile acids, 21 sterols, 15 free fatty acids, and 
16 endocannabinoids (since their in-source fragments may be isobaric with eicosanoids) 
were injected as neat solutions (Table S-2). LC-MS analysis revealed that all 238 
eicosanoid standards eluted between 1.0 and 5.75 minutes on the LC gradient (Fig. 1b), 
exhibited consistent peak shapes (FWHM < 0.1mins and tailing factor 0.8-1.2), and were 
chromatographically resolved from sterols (elution between 0.5 and 1.25 minutes), as well 
as fatty acids and endocannabinoids (elution between 6.0 to 7.0 minutes) (Fig. 1c). Bile 
acids exhibited chromatographic overlap with eicosanoids, though they exhibited noticeably 
wider peak widths and increased peak tailing (>1.5), particularly tauro-variants (Fig. 1c). 
Collectively this suggests that potential eicosanoids may be distinguished from other known 
metabolites using chemical characteristics, including accurate mass features, 
chromatographic retention, and peak shape. 
Monitoring of Eicosanoids in Human Plasma  
In humans, eicosanoids are produced locally in tissues, leak into the vasculature, and enter 
the systemic circulation.
3,4,21
 To determine the full catalog of eicosanoids present in 
circulation, human plasma was pooled and assayed using our directed, non-targeted LC-
MS methods. Human plasma revealed 134 distinct spectral peaks definitively identified as 
eicosanoids by precise matching of retention time, accurate mass, and tandem MS 
fragmentation pattern to one of 238 commercially available, known eicosanoid standards 
(Fig. 1d); these include numerous well described members of prostaglandin, HETE, DHET, 
HODE and additional eicosanoid families. Human plasma also revealed an additional 745 
spectral peaks across 56 distinct chemical formulas consistent with eicosanoids based on 
accurate mass (<2ppm) matching to one of 1125 theoretical eicosanoids in the LIPID MAPS 
database (Table S-1), retention time range (1.0 - 5.75 minutes), and peak shape (FWHM < 
0.1min and tailing factor 0.8-1.2) characteristics. These 745 spectral peaks include a 
number of entities found to be isobaric with the 134 definitively identified eicosanoids (Fig. 
2a). For example, the extracted ion chromatogram (XIC) for m/z 353.2333 exhibited 18 
isobaric chromatographic peaks with commercial standards accounting for 15, XIC for m/z 
375.2177 exhibited 32 isobaric chromatographic peaks with commercial standards 
accounting for only 3, and XIC for m/z 313.2384 exhibited 20 isobaric chromatographic 
peaks with commercial standards accounting for only 2 (Fig. 2a). Due to eicosanoids 
occupying a unique chemical space, these isobaric species are very likely to represent 
additional isobaric eicosanoids. For instance, search of the LIPID MAPS database for m/z 
313.2384 revealed a possible 29 eicosanoid species which could potentially correspond to 
these 20 observed features.  
Chemical Networking for Classification of Putative Known Eicosanoids 
The lack of commercial standards or reference tandem mass spectra have to date 
precluded identification or even chemical classification of unknown metabolites, including 
eicosanoids. To overcome this limitation, we reasoned that chemical similarity between a 
known eicosanoid and unknown molecule through comparison of spectral fragmentation 
patterns may allow for putative classification of unknown molecules as eicosanoids. To 
perform this analysis, we utilized chemical networking of spectral fragmentation for which 
tandem mass spectra for each unknown signal were compared to reference spectra from 
known compounds for presence of both identical mass fragments as well as similar mass 
shifts between fragment peaks.
41,42
 This approach allows experimental mass spectra to be 
matched to identical reference compounds for definitive identification, as well as in the 
absence of definitive identification, to be matched to related, non-identical compounds for 
putative chemical classification. To determine the utility of chemical networking for chemical 
classification, tandem MS fragmentation patterns were obtained for 238 eicosanoid 
commercial standards and 600 diverse, non-eicosanoid standards. Fragmentation patterns 
from these standards were chemically networked against over 50,000 metabolites for which 
spectral fragmentation data were publicly available, including additional tandem MS spectra 
for the 238 commercial eicosanoid standards collected by third parties. From this analysis, 
experimentally derived MS/MS spectra for 205 of the 238 eicosanoid standards were found 
to chemically network to corresponding spectra for the same compound present in the 
public library suggesting a sensitivity for matching of 86%. For those 33 of the 238 
eicosanoids that did not match, manual inspection of the tandem MS patterns revealed poor 
fragmentation of the parent ion, with often only the parent ion and loss of water present in 
the fragmentation spectra, precluding chemical matching which required a minimum of 6 
matched fragment peaks.  Among the 600 non-eicosanoid standards, none were found to 
chemically network with eicosanoids and were instead found to be chemically similar to one 
of 50,000 other molecules present in the public libraries, suggesting near perfect specificity 
for this approach. This specificity for chemical matching is consistent with the fact that 
eicosanoids, particularly cyclized variants, exhibit unique fragmentation mechanisms 
compared to other classes of compounds.
35,36,43-46
 Importantly, this high specificity is critical 
in limiting false positive matches when extending the chemical networking to unknown 
molecules for classification as eicosanoids.  
We first applied this chemical networking approach to the 18 unknown isobaric features at 
m/z 313.2384 (Fig. 2a). When tandem mass spectra from these chromatographic features 
at were subjected to the chemical networking strategy, 16 of the 18 features were 
specifically matched to one of the 238 eicosanoid standard compounds (Fig. 2b). Matched 
tandem MS spectral pairs were manually inspected and were found to be consistent with 
sharing a common base structure. Figure 2c shows one such comparison between the 
tandem mass spectra for 9,10-diHOME and an unknown isobaric peak at retention time 
3.13 minutes for which nearly identical fragmentation patterns are observed, indicating a 
very similar chemical structure. As such, matching of unknown compounds based on 
accurate mass and analogous fragmentation patterns to a known eicosanoid may allow 
such molecules to be classified as putative known eicosanoids. This approach suggests 
that chemical networking of unknown molecules to known chemical entities may be utilized 
to identify and study additional, high confidence, putative eicosanoids in human circulation. 
We next extended this chemical networking to all 745 spectral features identified as 
potential eicosanoids, based on accurate mass match to LIPID MAPS database entries, but 
for which no chemical standard or reference spectra was available. The results from the 
search were visualized as a mass spectral network (Fig. 3a), where top scoring, high 
confidence, chemical matches between experimental and reference fragmentation data 
were clustered together and displayed in order to represent chemical relationships among 
compound families. Of the 745 unknown experimental tandem MS spectra, 362 spectra 
were chemically networked with at least one eicosanoid standard and did not form 
secondary connections with any one of over 50,000 non-eicosanoid compounds present in 
the library repository, thereby classifying these 362 metabolites as putative known 
eicosanoids (Table S-3). The remaining 383 tandem MS spectra that did not chemically 
network with a known eicosanoid were mostly cluster clustered with either non-eicosanoid 
compounds (such as glucuronides, sterols, bile acids, and fatty acid ethyl esters) or 
clustered within themselves. The lack of similarity in tandem MS patterns with any reference 
spectra thereby suggest that these 383 chromatographic peaks cannot be considered as 
eicosanoid in nature without further evidence.  
Tandem MS spectral pairs from the chemical networking of 362 putative knowns with the 
238 reference eicosanoid standards were manually inspected and found to be consistent 
with both compounds sharing a common key substructure. For instance, in the molecular 
tandem MS network, the tandem MS spectra for 12-oxo LTB4 was clustered with four other 
tandem MS spectra from unknown signals (Fig. 3b). When the tandem MS spectra for 12-
oxo LTB4 and one of these unknowns was compared, it was observed that their patterns 
were highly similar thus indicating a common chemical structure (Fig. 3c-d). Importantly, 
algorithms for automated in silico fragmentation, such as CFM-ID 
47
 and MetFrag 
48
, were 
not able to accurately predict fragments for eicosanoid compounds, especially cyclized 
variants such as prostaglandins (Fig. S-2), given the unpredictable nature of eicosanoid 
fragmentation.
35,43-46,49-52
 However, these irregular fragmentation mechanisms allow for far 
fewer false positive matches to non-eicosanoid compounds. All 362 spectral matched were 
manually inspected to confirm similarity with 100 of these matches plotted in Figure S-3. 
Collectively, these analyses suggest that directed non-targeted LC-MS/MS in conjunction 
with chemical networking may be utilized to identify an additional 362 putative known 
eicosanoids in human circulation, thereby greatly extending the analytical breath of current 
approaches.  
Systems Chemistry for Identification of Novel Eicosanoids 
In addition to the ~500 known or putative known eicosanoids found in human plasma, we 
next sought to discover novel eicosanoids yet undescribed in any chemical database 
including LIPID MAPS, that may also be present in humans. Given the unique chemical 
properties of eicosanoids, we reasoned additional systems chemistry approaches may 
prove useful in identification of novel eicosanoids. Eicosanoids typically originate from one 
of a handful possible PUFAs, which are extensively modified through both enzymatic and 
non-enzymatic biosynthetic mechanisms. Across the 1125 theoretical eicosanoids, the 
extent of these modifications is nearly combinatorial where compounds exist at almost 
every Hn+2 and/or On+1 formula increment. These chemical patterns within eicosanoid 
families may be visualized by plotting the nominal mass versus the mass defect, here 
defined as the non-whole number value of the monoisotopic mass, for each compound 
within the family.
53
 For instance, among the prostaglandin family of eicosanoids, this type of 
plot reveals four distinct chemical series (Fig. 4a), where each series is incremented by 
addition of two hydrogens and the distance between each series represents the addition of 
a single oxygen. When extending this analysis beyond prostaglandins, distinct gaps in these 
formulaic patterns were readily observed. Among docosanoids starting at formula C22H34O2, 
database entries for eicosanoids were present for every addition of oxygen up to C22H34O6 
with the lone exception of C22H34O3 (Fig. 4b). When this formula’s calculated nominal mass 
of m/z 345.2435 was searched within the non-targeted LC-MS data collected from human 
plasma, a spectral peak at 4.72 minutes was matched and produced an tandem MS pattern 
that was nearly identical with that of the known docosanoid 10-HDoHE (Fig. 4c). Manual 
interpretation of the fragments showed that while 10-HDoHE has four double bonds 
between carbons 11 and 22, this novel eicosanoid only has three. This result indicated that 
the gaps in chemical series within the eicosanoid compounds may be utilized to identify 
putative novel eicosanoids.  
To determine if additional novel eicosanoids were present in human plasma, all 1125 
theoretical eicosanoids listed in the LIPID MAPS database were plotted as nominal mass 
versus their mass defect and computationally analyzed for missing values along Hn+2 and 
On+1 series (Fig. S-4). This analysis was extended to include one entry preceding the lowest 
formula value in the series as well as one entry past the final value as long as the number of 
oxygens was constrained between 3 and 8 and the number of hydrogens was between 24 
and 40, which represents the maximum and minimum values observed for known 
eicosanoids of 18 to 22 carbons. This analysis revealed 214 missing unique formulas 
spread across almost all subfamilies of eicosanoids with each one representing a potential 
novel eicosanoid. We searched in human plasma for compounds with accurate masses 
corresponding to these 214 chemical formulas using our directed, non-targeted LC-MS 
approaches, findings 184 distinct chromatographic peaks present at 45 of the 214 chemical 
formulas, with each of these peaks  having accurate mass (<2ppm) matching to a 
theoretical formula, a retention time range (1.0 - 5.75 minutes), and a peak shape (FWHM < 
0.1min and tailing factor 0.8-1.2) consistent with eicosanoids. To determine if these peaks 
were structurally related to known eicosanoids, targeted tandem MS spectra was collected 
for each of the 184 chromatographic peaks and chemically networked. The resulting 
analysis revealed that 46 of the 184 putative novel eicosanoids clustered with at least one 
known eicosanoid and none of the 50,000 non-eicosanoid metabolites, indicating structural 
similarity is present between these putative novel eicosanoids with known members of the 
compound families (Table S-4). Each of the 46 spectral pairs resulting from the chemical 
networking search were manually inspected and found to be consistent with those of the 
eicosanoid reference standards with 5 examples shown in Figure S-5. One such example is 
an unknown compound m/z 347.2600, which corresponds to the chemical formula 
C22H36O3, and was spectrally matched to the octadecanoid 13-HoTrE (Fig. S-5a). 
Comparison of the tandem MS fragmentation patterns between the unknown and known 
compounds revealed that all carboxyl-containing fragments from carbons C7 to C1 were 
identical between the two compounds while all carboxyl-containing fragments from carbons 
C12 or C13 were shifted by 54.0472 daltons. This shift indicates that between carbons C12 
and C7 there is an additional C4H6 present in the novel eicosanoid, and its structure is 
consistent with a novel set of HDoHE family of compounds in which two double bonds are 
converted to single bonds. This systems chemistry approach thereby enables discovery of 
novel eicosanoids, identifying an additional 46 putative novel eicosanoids in human 
circulation.  
Relation of eicosanoids to human inflammation 
Eicosanoid lipid mediators play critical roles in regulating systemic pro- and anti-
inflammatory responses in the setting of both acute infection and chronic inflammation.
3,5,22
  
To date, however, biological functions have only been described for a fraction of the ~150 
commonly studied eicosanoids found in human plasma. To determine if any of the hundreds 
proposed putative known and putative novel eicosanoids have roles in human biology 
similar to those of known eicosanoids, plasma samples from 1500 fasting, community-
dwelling individuals were assayed for eicosanoids using directed, non-targeted LC-MS. 
Definitive known, putative known, and putative novel eicosanoids were mapped to plasma 
samples by matching of retention time, accurate mass, and tandem MS fragmentation 
patterns, with focus on those eicosanoids previously observed in pooled plasma and 
present with signal-to-noise ratios above LOQ level in >95% of individuals. Eicosanoids 
were statistically associated with common clinical features linked to systemic inflammation, 
including advancing age and obesity (measured by body mass index [BMI]), as well as high 
sensitivity C-reactive protein (CRP), a well-established marker of systemic inflammation 
(Fig. 5).
54,55
 For both clinical features and CRP measures, dozens of both known and 
putative eicosanoids were found to be highly related at ‘metabolome-wide’ adjusted 
statistical thresholds of p<1x10
-5
, with a number of molecules even reaching ‘high 
confidence levels’ of p<1x10-20. For each clinical phenotype, both positive and negative 
associations were observed (Table S-5), suggesting both pro- and anti-inflammatory 
activities for eicosanoids, consistent with the described function of eicosanoids. For 
identifiable eicosanoids, production of arachidonic acid metabolites (e.g. HETE's and 
HpETE's) showed positive correlation with BMI and CRP levels, suggesting a pro-
inflammatory role for these molecules, while DiHDPA and DiHETrE metabolites showed 
negative correlations, suggesting an anti-inflammatory role; similar patterns have been 
observed in cellular systems upon acute activation of inflammatory pathways.
56
 Moreover, 
particular putative eicosanoids, such as m/z 327.2176 were found to be commonly 
associated with multiple correlates of inflammation (p-value 8e
-35
 for BMI, 7e
-27
 for CRP), 
whereas other putative eicosanoids, such as m/z 349.2020 (p-value 1e
-35
), m/z 327.2162 (p-
value 2e
-20
), and m/z 347.2590 (p-value 2e
-12
) were specifically associated with age, BMI or 
CRP levels, respectively, suggesting both universal and specific mediators of inflammation. 
Interestingly, for all three clinical phenotypes examined a number of putative known and 
putative novel eicosanoids were found to be highly associated, highlighting the discovery 
potential.  
 
DISCUSSION 
In this report, we describe new approaches for the assay and identification of eicosanoids in 
human biosamples using directed, non-targeted LC-MS coupled to computational chemical 
networking. While traditional targeted methods for studying eicosanoids can produce very 
sensitive and quantitative measurements, directed, non-targeted analysis greatly expands 
upon the spectrum of eicosanoids measurable in complex organisms, enable discovery of 
hundreds of new eicosanoids in humans, and provide a foundation for new insight into the 
role of bioactive lipids in mediating human health and disease. This approach makes use of 
directed extraction whereby samples were prepared using methods designed specifically for 
isolation of eicosanoids (versus a general Bligh-Dyer lipid extraction), chromatographic 
separation designed to separate the extensive array of eicosanoid isomers, non-targeted 
mass spectrometric measured allowing capture of all possible eicosanoid species, and 
MS/MS chemical networking allowing for identification of previously unreported eicosanoids. 
Application of these approaches to human plasma revealed hundreds of putative 
eicosanoids, advancing upon the current state of the art analytical techniques and greatly 
expanding the current chemical repertoire, revealing 134 definitively known, 362 putative 
known, and 46 putative novel eicosanoids observable in human plasma. These molecules 
were validated by a number of methodologies, including extensive chemical networking of 
mass spectral fragmentation patterns and manual annotation of a subset of eicosanoids. 
These methods were also found to have high specificity for eicosanoid compounds given 
the unique and irregular mechanisms by which they fragment. Many of the putative 
eicosanoids described herein were found to be highly associated with both pro- and anti-
inflammatory clinical characteristics and measures in a cohort of 1500 individuals. These 
eicosanoids and tandem MS spectral patterns have been provided in a database as a rich 
resource to the scientific community for further study and discovery (Supplemental 
Information). Additionally, as many compound classes exhibit similar chemical patterning 
as observed in eicosanoids, such as PUFAs, endocannabinoids, FAHFAs and sterols, this 
approach could be adapted to perform similar discovery based work in these other chemical 
families potentially expanding their number of measureable entities and revealing additional 
interesting biology. 
While greatly expanding upon the number of eicosanoids reported in human plasma, the 
current experimental and computational approaches will continue to shed even more insight 
into eicosanoid biology as they are applied in complementary systems. While the current 
studies focus on human plasma, undoubtedly additional eicosanoids will be found localized 
to particular cells or tissues, or induced under particular biological conditions. Moreover, it is 
important to note that our described approaches exclude eicosanoids with novel 
fragmentation mechanisms different from those exhibited by chemical standards and 
therefore it is possible that a number of additional eicosanoids may exist; assay of these 
molecules will however require orthogonal systems. Finally, while our human studies across 
1500 individuals focus upon those eicosanoids that were initially discovered in pooled 
human plasma and universally present, a number of additional known and putative novel 
eicosanoids were observed in specific individuals; lack of additional patient plasma however 
for follow-up validation preclude study of these signals.    
As commercial standards only cover about ~20% of total unique theoretical eicosanoids, 
targeted studies on inflammatory pathways have been confined to studying the same 
subset of compounds despite potentially hundreds more eicosanoids being present in 
human circulation. As many of these compounds are likely modulated under particular 
conditions such as acute systemic inflammation or during development, or may occur in 
particular tissues and cells in a localized manner, their study is critical for advancing our 
understanding of these complex signaling processes. Furthermore, as a number of these 
putative eicosanoids were found to be highly associated with clinical characteristics and 
markers of inflammation, future studies will aim to further characterize these molecules 
including identifying the biochemical pathways responsible for their production and 
degradation, localizing individual eicosanoids to specific tissues of origin, establishing 
causal pro- and anti-inflammatory molecules, and elucidating their downstream signaling 
mechanisms. Importantly, the studies described herein highlight the discovery potential of 
directed, non-targeted LC-MS and corresponding computational chemical networking 
approaches, underscore the breath, complexity and diversity of eicosanoids present in 
human circulation, and provide a foundation for new insight into the role of bioactive lipids in 
mediating human health and disease.  
  
METHODS 
Chemicals and consumables   
Non-deuterated and deuterated chemical standards (See Table S-2) were purchased from 
Cayman Chemical and IROA Technologies. LCMS grade solvents used for sample 
preparation and metabolomic analysis including methanol, acetonitrile, water, and 
isopropanol were purchased from Honeywell International Inc while LCMS grade ethanol 
and acetic acid were purchased from Sigma-Aldrich. All pipetting instruments and 
consumables were purchased from Eppendorf. For sample preparation, 250L V-bottom, 
500L V-bottom, and 1.2mL deep well 96-well plates were purchased from Thermo 
Scientific, Axygen and Greiner, respectively. LCMS amber autosampler vials and tri-layer 
vial caps were purchased from Agilent Technologies and 300L glass inserts were 
purchased from Wheaton. Strata-X polymeric 96-well (10mg/well) solid phase extraction 
plates as well as Kinetex C18 1.8m (100 x 2.1 mm) UPLC columns were purchased from 
Phenomenex Inc. UPLC BEH RP-18 guard columns were purchased from Waters Inc. EZ-
Pierce 20m aluminum foil was purchased from Thermo Scientific. Pooled plasma was 
purchased from BioreclamationIVT.  
LC-MS and spectral data handling  
LC-MS was performed using a Thermo Vanquish UPLC coupled to a Thermo QExactive 
Orbitrap mass spectrometer. For data processing, in-house R-scripts were used to perform 
initial bulk feature alignment, MS1-MS2 data parsing, pseudo DIA-to-DDA MS2 
deconvolution, and CSV-to-MGF file generation. RAW to mzXML file conversion was 
performed using MSconvert version 3.0.9393 (part of the ProteoWizard Software Suite). 
Feature extraction, secondary alignment, and compound identification were performed 
using both mzMine 2.21 as well as Progenesis QI software suites. Statistical analysis was 
performed using R (3.3.3).  
Plasma eicosanoid extraction  
For preparation of plasma, samples were thawed at 4⁰C over 8 hours in light free 
conditions. Once thawed, plasma was mixed thoroughly by orbital shaking at 500 rpm at 
4⁰C for 15 minutes. Cold (-20⁰C) ethanol containing 20 deuterated eicosanoid internal 
standards was used to precipitate proteins and non-polar lipids as well as extract 
eicosanoids from the plasma through the addition of 1:4 plasma:ethanol-standard mixture to 
each well, shaking at 500rpm at 4⁰C for 15 minutes, and centrifugation at 4200 rpm at 4⁰C 
for 10 minutes. To allow for more efficient SPE loading, 65L of supernatant was 
transferred to an Axygen 500L V-bottom 96-well plate where each well contained 350L of 
water. A second extraction of the protein pellet was performed by gently adding 65L of -
20⁰C ethanol (containing no standards), gently hand vortex mixing for 30 seconds, and 
transferring another 65L aliquot of supernatant to the same Axygen V-bottom 96-well 
plate, at which point samples are ready for SPE plate loading. The Phenomenex Strata-X 
polymeric 10mg/mL 96-well SPE plate was washed by sequentially adding and vacuum 
assisted eluting 600 L of methanol and 600L of ethanol and equilibrated by addition of 
1.2mL of water per well. All solvents were added while taking care not to let wells run dry 
between pull through. The entire volume of the water-diluted samples were added to the 
SPE wells and allowed to gravity elute. Once the sample volume reached the top of the 
SPE bed, 600L of 90:10 water:methanol was added to each well and slowly pulled through 
(5 mmHg vacuum) until no liquid was visualizen in the wells. Wells were further dried by 
increasing vacuum to 20 mmHg for 60 seconds. Bound metabolites were then eluted into an 
Axygen 500L V-bottom 96-well plate by addition of 450L of ethanol to each SPE plate 
well, with slow pull through (5 mmHg vacuum) after 120 second equilibration.  Eluent was 
immediately dried in vacuo using a Thermo Savant vacuum concentrator operated at 35⁰C. 
Once dry, samples were resuspended in a solution containing 40:60:0.1 
methanol:water:acetic acid as well as 10M CUDA internal standard by addition of 50L of 
solution to each well, immediately sealing the plate, vortex mixing at 500rpm at 4⁰C for 10 
minutes. Samples were immediately transferred to a Greiner deep-well 96-well plate with 
each well containing a Wheaton 300L glass insert (to prevent the rapid degradation of 
eicosanoid signals typically observed when eicosanoids are prepared in polypropylene 
plates). The sample plate was then immediately sealed and centrifuged at 500 rpm at 4⁰C 
for 5 minutes to removed any air bubbles that might have formed within the glass inserts. 
Samples were stored at less than 2 hours at 4⁰C until LC-MS analysis.   
LC-MS/MS data acquisition 
Once prepared, 20L of sample was injected onto a Phenomenex Kinetex C18 (1.7m 
particle size, 100 x 2.1 mm) column and separated using mobile phases A (70% water, 30% 
acetonitrile and 0.1% acetic acid) and B (50% acetonitrile, 50% isopropanol, 0.02% acetic 
acid) running the following gradient: 1% B from -1.00 to 0.25 minutes, 1% to 55% B from 
0.25 to 5.00 minutes, 55% to 99% B from 5.00 to 5.50 minutes, and 99% B from 5.50 to 
7.00 minutes. Flow rate was set at 0.375 mL/min, column temperature and mobile phase 
pre-heater was set at 50⁰C, needle wash was set for 5 seconds post-draw using 
50:25:25:0.1 water:acetonitrile:isopropanol:acetic acid. Mass detection was performed using 
a Thermo QExactive orbitrap mass spectrometer equipped with a heated electrospray 
ionization (HESI) source and collision-induced dissociation (CID) fragmentation. HESI probe 
geometry was manually optimized about the x, y and z axis by infusing CUDA and PGA2 
standards into the mobile phase stream at 1%, 50% and 99% B. Final geometry was probe 
height of 0.75 B-C (between B and C markers about 3/4 the way to C), x-offset of 1 mm left 
of center, and a Y-offset of 1.70 according to the micrometer. Source settings used for all 
samples were: negative ion mode profile data, sheath gas flow of 40 units, aux gas flow of 
15 units, sweep gas flow of 2 units, spray voltage of -3.5kV, capillary temperature of 265⁰C, 
aux gas temp of 350⁰C, S-lens RF at 45. Data was collected using an MS1 scan event 
followed by 4 DDA scan events using an isolation window of 1.0 m/z and a normalized 
collision energy of 35 arbitrary units. For MS1 scan events, scan range of m/z 225-650, 
mass resolution of 17.5k, AGC of 1e6 and inject time of 50ms was used. For tandem MS 
acquisition, mass resolution of 17.5k, AGC 3e5 and inject time of 40ms was used. Once 
target eicosanoids were discovered, additional tandem MS spectra was collected in a 
targeted fashion using Inclusion Lists to obtain high quality spectra for each compound. 
Chemical networking of tandem MS spectra 
Tandem MS spectra was collected in a targeted fashion for all observed chromatographic 
peaks in pooled plasma matching all known, putative known and putative novel eicosanoids 
based on accurate mass (m/z for [M-H]- within 5ppm mass error). Tandem MS spectra for 
each chromatographic peak were averaged, extracted and saved as individual MGF files. 
These MGF files (1063 in total) were uploaded to GNPS (http://gnps.ucsd.edu) for chemical 
networking analysis. Analysis was performed using both Networking and Dereplication 
workflows. For Networking the following thresholds: Precursor Ion Mass Tolerance of +/- 
0.05Da, Fragment Ion Mass Tolerance of +/-0.05Da, Minimum Cosine Score of 0.60, 
Minimum Matched peaks of 6, TopK of 10, Maximum Connected Component Size of 500, 
Minimum Cluster Size of 1, Library Score Threshold of 0.85, Minimum Matched Library 
Peaks of 6, Analog Search turned On, Maximum Analog Mass Difference of 85Da, Filter 
Precursor Window turned On, all other filters turned off. For Dereplication the following 
thresholds were used: Precursor Ion Mass Tolerance of +/- 0.05Da, Fragment Ion Mass 
Tolerance of +/-0.05Da, Minimum Cosine Score of 0.60, Minimum Matched peaks of 6, 
Analog Search turned On, Maximum Analog Mass Difference of 85Da, Filter Precursor 
Window turned On, all other filters turned off. All primary and third party databases, 
including our in-house database from the 238 eicosanoid commercial standards were used 
for matching. For all matches to library reference spectra, only the top scoring hit was 
considered. All resulting matches were manually checked for consistency in tandem MS 
fragmentation patterns between the library reference spectra and the experimental spectra.  
Eicosanoid analysis of human samples  
For evaluation of eicosanoids across a human cohort, we used fasting plasma specimens 
collected in 2005–2008 from N=1500 participants (mean age 66.2±9.0 years, 55% women) 
of the community-based Framingham Heart Study Offspring Cohort (Table 1).
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  All 
participants provided written informed consent. All study protocols were approved by the 
Brigham and Women’s Hospital, Boston University School of Medicine, National Institute for 
Health and Welfare (Finland) and UC San Diego Institutional Review Boards. At the time of 
specimen collection, the participants underwent a medical history, physical, and laboratory 
assessment for high sensitivity C-reactive protein (CRP). CRP was measured using an 
immunoturbidometric method on a Roche Cobas 501. The intra- and inter-assay CVs for 
CRP were 2.5% and 4.5%, respectively.  
Plasma samples were prepared and LC-MS analysis performed as described above. All 
data was converted to 32-bit mzXML data format using MSconvert version 3.0.9393 (part of 
the Proteowizard software suite). Initial bulk retention time correction was performed as 
described previously
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 whereby all data files for a given sample set were loaded into 
Mzmine 2.21 and the sample specific retention times for all deuterated internal standards as 
well as approximately 50 endogenous landmark peaks (defined as chromatographic 
features with %CV < 50% across all samples, minimum peak height of 500,000 counts and 
a no isobaric peaks within +/- 30 seconds of target) were exported and used to model non-
linear retention time drift within each sample using cubic smoothing splines with 8 to 16 
degrees of freedom within the model. Using these sample specific models, the retention 
times for all MS1 and MS2 scans with each mzXML file were adjusted so that the maximum 
drift observed was reduced from (on average) 0.15 minutes to 0.025 minutes across as 
many as 3000 sample injections. Parameters used for Mzmine peak extraction are as 
follows: Mass Detection threshold of 250k counts, Chromatogram Builder  0.025 minute min 
time span, min height of 500k counts and m/z tolerance of 5ppm, Chromatogram 
Deconvolution (Local Minimum Search) chromatographic threshold of 80%, search 
minimum RT range of 0.03 min, minimum relative height of 0.4%, min height of 500k 
counts, top-edge ratio of 1.2, peak duration of 0.025 to 0.5 minutes, Join Aligner mz 
tolerance of 5ppm, RT tolerance of 0.4 minutes, weight for retention and mass both at 90, 
Peak List Rows Filter retaining only peaks present in at least 50% of data files. Custom 
Library Search for all known, putative known and putative novel Eicosanoids was performed 
using an RT tolerance of 0.1 minutes and a mass tolerance of 5 ppm. Resulting features 
were manually denoised by visual inspection using the Mzmine peak list viewer where 
features exhibiting abnormal/poor peak shapes, inconsistent peak shapes and/or drastic 
shifts in retention time were deleted.  
Exported peak lists for each file group were normalized by centering the batch mean for 
each m/z-feature to the global mean for all batches within the run set. Once normalized, 
features present in the MS1 data were filtered based on signal reliability by the used of the 
'dtwclust' R-module as described previously where essentially all features were hierarchical 
clustered and automatically parsed based on patterns exhibited within their intensity profile 
across all samples when plotted with respect to injection order with features exhibiting 
stable patterns being retained while those exhibiting patterns indicative of chemical 
instability, misalignment or highly random distributions were removed.  
For statistical analyses of human data, we constructed linear regression models relating 
each of the known, putative known, and putative novel eicosanoids with age, body mass 
index, and C-reactive protein. Prior to entry into regression analyses, eicosanoid variables 
were logarithmically transformed and standardized. Statistical analyses were performed 
using R v3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). 
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FIGURE LEGENDS 
Fig. 1: Directed non-targeted LC-MS based measure of eicosanoids in humans. a, 
Histogram illustrating the high degree of isomerism amongst eicosanoids with number of 
database entries for each mass to charge (m/z). b, Extracted ion chromatograms for all 238 
commercial eicosanoid standards. c, A mass defect versus retention time plot for 
eicosanoids and related compounds. d, Extracted ion chromatograms for all 134 spectral 
peaks observed in pooled plasma that were matched to commercial eicosanoid standards. 
Fig. 2: Identification of eicosanoids in human plasma. a, Extracted ion chromatograms 
for m/z's 353.2333, 375.2177 and 313.2384 with the red asterisks indicating peaks for 
which commercial standards are available. b, Tandem MS spectra for all peaks present at 
m/z 313.2384, excluding the two peaks for which standards were available. Tandem MS 
spectra were clustered against known eicosanoids, with top 7 correlations shown. c, 
Comparison of tandem MS spectra from m/z 313.2384 chromatographic peak at 3.27 
minutes with that of 9,10-DiHOME, revealing similar chemical structures. 
Fig. 3: Chemical networking for discovery of eicosanoids. a, Tandem MS spectra for 
the 745 chromatographic features matching to chemical formulas of known eicosanoids was 
clustered against tandem MS for the 238 commercial standards with the resulting 
correlations displayed as a simplified molecular network. Here, red nodes indicate tandem 
MS spectra for commercial standards with blue nodes indicating tandem MS spectra from 
the 745 unknown compounds, with the size of the nodes reflecting number of unique 
spectra contained within each node. b, Expanded view of the 12-oxo-LTB4 node (red box 
from 3a) showing the observed m/z and retention time in minutes within parenthesis. c, 
Overlay of tandem MS spectra from 12-oxo-LTB4 and m/z 367 at 1.62 minutes showing 
high degree of similarity. d, Manual annotation of tandem MS fragments of m/z 367 at 1.62 
minutes and how they relate to the structure of 12-oxo-LTB with blue arrows indicating 
identical fragments and orange arrows indicating a shift of +CH4O between carbons 11 and 
13. See also Figure S3. 
Fig. 4: Systems chemistry for identification of novel eicosanoids. a, Mass defect 
versus nominal mass plot of 15 chemical formulas, which compose the prostaglandin series 
of eicosanoids, illustrating common chemical patterns within eicosanoid families. b, 
Example of a series of chemical formulas that exhibit a gap, or missing formula entry, in the 
overall pattern. Untargeted data was searched again at these formula masses to determine 
if chromatographic features were present. c, Tandem MS spectra from one of these missing 
entries (C22H34O3) was found to be highly similar to the tandem MS spectra for 10-HDoHE 
with both sharing common fragments (blue arrows) as well as analogous fragments that 
were shifted by the mass of two hydrogens (orange arrows). Manual annotation indicates 
that the novel eicosanoid molecule is identical to 10-HDoHE with the exception that it 
contains 3 instead of 4 double bonds between carbons 11 and 22. See also Figure S4 and 
S5. 
 Fig. 5: Eicosanoid correlates of human inflammation. Associations among known (blue), 
putative known (red), and putative novel (green) plasma eicosanoids with age, body mass 
index, and C-reactive protein across 1500 individuals. Data points represent the negative 
Log P values derived from linear regression models relating each eicosanoid with a given 
clinical variable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES LEGEND 
 
Table 1: Clinical characteristics of human cohort. Values are displayed as means ± SD, 
frequencies, or median and 25
th
, 75
th
 percentiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL FIGURE LEGENDS 
Fig. S1. Flow chart for eicosanoid discovery. Flow chart showing experimental design of 
how directed non-targeted LC-MS/MS in conjunction with chemical networking was used to 
identify definitive known, putative known and putative novel eicosanoids. 
Fig. S2. Performance of automated tandem MS fragment assignment tools.  
(A)Tandem MS spectra from commercial standards were inputed into the MetFrag webtool 
with LipidMaps serving as the library. On average, Metfrag was only able to assign ~5% of 
fragment peaks to corresponding chemical structures. Here are two examples using a linear 
and a cyclic eicosanoid where both results showed poor ability to assign spectral fragments 
to chemical structures with almost all of the dominant fragments not assigned. Note that 
matched peaks were re-colored red for visibility. (B) In silico prediction of tandem MS 
fragments of commercial standards were subjected to fragmentation using CFM-id. Here is 
a typical example using a cyclic eicosanoid where many of the observed fragments fail to be 
predicted. CFM-id performed notably better at predicting fragments for linear eicosanoids, 
however, many fragments were still left unpredicted. 
Fig. S3. Examples of experimental tandem MS spectral matches to tandem MS 
spectra from eicosanoid commercial standards. Each example shows the tandem MS 
spectra from the unknown compound (black) above the tandem MS spectra of the standard 
(green). Comparison of the spectra reveal presence of identical MS fragment peaks as well 
as, in some cases, peaks consistently shifted by a given mass indicating that the unkown 
compounds share a similar structure to that of the eicosanoid commercial standard.  
Fig. S4. Mass defect plots used for identification of chemical formulas potentially 
belonging to novel eicosanoid compounds. (A) For each eicosanoid entry in the 
LipidMaps library, the nominal mass was plotted against the mass defect to reveal patterns 
in chemical formulas which compose the 1149 unique compounds. (B) By searching for 
gaps in the chemical iterations within each chemical family, ‘missing’ entries were identified 
and plotted in red. (C) Once data for each of the missing formulas was extracted and 
searched via chemical spectral networking, all formulas resulting in positive analog matches 
were left plotted in red relative to all entries from eicosanoids in Lipid MAPS. 
Fig. S5. Annotation of tandem MS spectra for potentially novel eicosanoids. (A) m/z 
347.2591 at 5.58 minutes. (B) m/z 345.2434 at 5.37 minutes. (C) m/z 345.2434 at 5.47 
minutes. (D) m/z 345.2434 at 4.94 minutes. (E) m/z 357.2646 at 2.32 minutes. 
 
 
 
 
SUPPLEMENTAL INFORMATION TABLE LEGENDS 
 
Table S1. List of 1125 LIPID MAPS database entries used as source database for mining 
non-targeted data for putative known and putative novel eicosanoids. 
 
Table S2. List of all commercial standards used for assignment of definite known 
eicosanoids as well as identification of putative known and putative novel eicosanoids 
through chemical networking. 
 
Table S3. Results for chemical networking for putative known eicosanoids. 
 
Table S4. Results for chemical networking for putative novel eicosanoids. 
 
Table S5. Results from statistical analysis for Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL INFORMATION DATA PACKAGE 
 
Data_Package.zip - All MS/MS spectra (1 spectra per file) of eicosanoid commercial 
standards, the 362 putative known eicosanoids and the 46 putative novel eicosanoids. The 
file names here correspond with the input file names in Tables S3 and S4. 
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Figure S1. Flow chart showing experimental design of how directed non-
targeted LC-MS/MS in conjunction with chemical networking was used to 
identify definitive known, putative known and putative novel eicosanoids. 
Figure S1 
Figure S2. Performance of automated tandem MS fragment assignment tools.  
(A)Tandem MS spectra from commercial standards were inputed into the 
MetFrag webtool with LipidMaps serving as the library. On average, Metfrag 
was only able to assign ~5% of fragment peaks to corresponding chemical 
structures. Here are two examples using a linear and a cyclic eicosanoid 
where both results showed poor ability to assign spectral fragments to 
chemical structures with almost all of the dominant fragments not assigned. 
Note that matched peaks were re-colored red for visibility. (B) In silico 
prediction of tandem MS fragments of commercial standards were subjected to 
fragmentation using CFM-id. Here is a typical example using a cyclic 
eicosanoid where many of the observed fragments fail to be predicted. CFM-id 
performed notably better at predicting fragments for linear eicosanoids, 
however, many fragments were still left unpredicted. 
Prostaglandin A2 
MS/MS peaks matched: 5 of 115  
5-HETE 
MS/MS peaks matched: 6 of 84 
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Experimental Tandem  
MS Spectra Predicted Tandem  
MS Spectra 
Figure S2-B 
Figure S3. Related to Figure 3. Examples of experimental tandem MS 
spectral matches to tandem MS spectra from eicosanoid commercial 
standards. Each example shows the tandem MS spectra from the unknown 
compound (black) above the tandem MS spectra of the standard (green). 
Comparison of the spectra reveal presence of identical MS fragment peaks as 
well as, in some cases, peaks consistently shifted by a given mass indicating 
that the unkown compounds share a similar structure to that of the eicosanoid 
commercial standard.  
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Figure S3 (Continued) 
Figure S4. Mass defect plots used for identification of chemical formulas 
potentially belonging to novel eicosanoid compounds. (A) For each eicosanoid 
entry in the LipidMaps library, the nominal mass was plotted against the mass 
defect to reveal patterns in chemical formulas which compose the 1149 unique 
compounds. (B) By searching for gaps in the chemical iterations within each 
chemical family, ‘missing’ entries were identified and plotted in red. (C) Once 
data for each of the missing formulas was extracted and searched via 
chemical spectral networking, all formulas resulting in positive analog matches 
were left plotted in red relative to all entries from eicosanoids in LipidMaps. 
 
 
Figure S4 
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Figure S5. Related to Figure 4. Annotation of tandem MS spectra for 
potentially novel eicosanoids. (A) m/z 347.2591 at 5.58 minutes. (B) m/z 
345.2434 at 5.37 minutes. (C) m/z 345.2434 at 5.47 minutes. (D) m/z 
345.2434 at 4.94 minutes. (E) m/z 357.2646 at 2.32 minutes. 
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